Blood Review Time

Three factors make Blood's timeline more predictable:

Lower desk rejection rate. At ~40-50%, Blood sends more papers to review than Nature (~80% desk rejection) or Cell (~70-80%). This means more papers get a chance at peer review, and the editorial triage is less of a bottleneck.

Well-defined reviewer community. Hematology is a specific specialty with a identifiable reviewer pool. The ASH membership directory gives editors a clear map of who reviews what. Reviewer recruitment that takes 3-4 weeks at interdisciplinary journals often takes 1-2 weeks at Blood.

Broad scope within one specialty. Blood publishes basic, clinical, and translational hematology. This means papers rarely get desk-rejected for "scope mismatch" the way they do at journals with narrower editorial identities. If the paper is hematology, the scope question is usually settled.

Blood reviewers evaluate the paper within the standards of their hematology subspecialty. The review criteria shift by paper type:

For basic hematology: Is the mechanism novel? Are the model systems appropriate? Does the finding advance understanding of blood cell biology or blood disease?

For clinical hematology: Is the evidence strong enough to inform treatment? Are the endpoints clinically meaningful? Is the patient population representative?

For translational work: Does the bench-to-bedside bridge hold? Is the human relevance supported by data, not just discussion?

Blood reviewers tend to be constructive. The ASH culture emphasizes improving papers rather than gatekeeping. Revision requests are usually reasonable and focused.

When Blood editors see hematology merit but the paper isn't quite at the flagship threshold, they offer a redirect to Blood Advances (IF ~7). This is the most common alternative outcome after desk rejection.

The redirect includes the editor's assessment and sometimes the initial reviewer comments. This speeds up the process at Blood Advances significantly. Many papers that end up in Blood Advances went through this route.

Taking the redirect is usually the right call. Blood Advances shares the ASH brand, the same reviewer community, and reaches the same hematology audience.

Submit if:

• the finding advances hematology (basic, clinical, or translational)
• the paper is clearly about blood cells, blood diseases, or blood-related biology
• the methodology is rigorous for hematology-level scrutiny
• you want the ASH flagship's audience and credibility

Think twice if:

• the hematology connection is secondary (the real story is immunology, oncology, or biochemistry)
• Blood Advances would reach the same audience with less competition
• Leukemia, Haematologica, or JCO is a more specific fit for the topic
• the finding is incremental for the hematology community

A free manuscript scan can help assess whether the hematology framing and evidence strength meet Blood's editorial expectations.

How long does Blood take to desk-reject?

Typically 1-3 weeks. The desk rejection rate (~40-50%) is lower than most top-tier journals.

How long does Blood peer review take?

4-6 weeks for reviewer reports, 6-10 weeks total to first decision.

Why is Blood faster than Nature or Cell?

Lower desk rejection rate, well-defined hematology reviewer pool, and broad scope that minimizes scope-mismatch rejections. The process is designed for efficiency within a single specialty.

What happens if Blood offers a redirect to Blood Advances?

The paper transfers with the editor's assessment, which typically speeds up review at Blood Advances. Take it seriously.